A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Alirocumab in Chinese Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- Sponsors Sanofi
- 04 Dec 2017 Status changed from active, no longer recruiting to completed.
- 25 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2017 Planned End Date changed from 1 Jan 2018 to 27 Nov 2017.